Blog
RSS FeedPosted by Michael Wonder on 09 Dec 2021
Consensus lacking on ‘value’ for new anti-cancer drugs
8 December 2021 - The high price tag of new anticancer drugs has fuelled debate about the value of these treatments, ...
Posted by Michael Wonder on 11 Apr 2019
The role of regulators in establishing added benefit of novel therapies
11 April 2019 - Regulators have a role to play in ensuring that there is a solid evidence base to support ...
Posted by Michael Wonder on 23 Jan 2018
Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries
23 January 2018 - Although health technology assessment systems base their decision making process either on economic evaluations or comparative clinical ...
Posted by Michael Wonder on 14 Oct 2017
EMA responds to BMJ article questioning benefits of recent cancer drug approvals
13 October 2017 - As more cancer drugs are approved and prices continue to rise, questions have circulated on whether ...
Posted by Michael Wonder on 05 Oct 2017
Cancer patients given new drugs that won’t help them
5 October 2017 - Most new cancer drugs are given to patients without any evidence that they extend or improve ...